Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for
 the treatment of patients with cervical HPV-16 and/or HPV-18 infections; to analyze the HPV
 type infections and clinical negative conversion.
100 patients with positive HPV-16 and HPV-18 infection are randomized into interferon gel
 group and control group at ratio of 1:1 (50 patients in treatment group and 50 patients in
 control group). The patients in treatment group received 1g recombinant human α-2b interferon
 gel every other day for consecutive 6-10 courses of treatment, whereas no treatment was
 conducted in control group.
Inclusion Criteria:

 -  Age 25 to 65 years of age with the sex life of female patients;

 -  HPV DNA typing test for HPV-16 and/ or HPV-18 positive in 1 month.

 Exclusion Criteria:

 -  Patients with cervical intraepithelial neoplasia Ⅱ / Ⅲ, cervical cancer;

 -  Associated with fungal vaginitis, trichomonas vaginitis, HIV positive patients;

 -  Associated with acute, severe bacterial or viral infection;

 -  Autoimmune diseases;

 -  Within 3 months before screening patients used corticosteroids, immunosuppressants or
 other antiviral drugs;

 -  Allergies or allergy to the drug known ingredients;

 -  History of suffering CNS diseases, epilepsy and/or psychological disorder;

 -  Pregnant and lactating women;

 -  The researchers do not consider it appropriate clinical trials.